Posted in | News | Nanomedicine | Nanomaterials

Leonardo Secures Grant to Commercialize Nanoparticle Drug Delivery System

Arrowhead Research Corporation (Nasdaq: ARWR) announced today that its portfolio company, Leonardo Biosystems, has received a $2.5 million grant from the Texas Emerging Technology Fund, a state fund established to accelerate commercialization of new technologies.

Leonardo Biosystems, co-founded by prominent nanoscientist Dr. Mauro Ferrari, professor at the University of Texas, and Arrowhead’s, CEO Dr. Christopher Anzalone, is engineering a multi-stage drug delivery platform to improve the effectiveness of drug therapy, particularly for cancer.

The Texas Emerging Technology Fund was established by the Texas Legislature at the urging of Governor Rick Perry. The Fund’s commercialization awards provide selected, early-stage investments in new, technology-based, private entrepreneurial entities that collaborate with public or private institutions of higher education in Texas, and which, if successful, may provide significant economic benefit to the state.

“We are honored that our company has been recognized by the blue ribbon ETF Advisory Board as a promising channel for providing economic development for the state of Texas,” said Dr. Bruce Given, Leonardo’s CEO. “Leonardo’s proprietary nanoparticle delivery system is designed to overcome the body’s natural defense mechanisms which make it difficult or impossible to effectively deliver many promising therapeutics, especially in cancer. This award from the ETF allows us to keep this crucial technology in Texas, where we hope to develop it to its full potential.”

Source: http://www.arrowheadresearch.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Arrowhead Pharmaceutical. (2019, February 13). Leonardo Secures Grant to Commercialize Nanoparticle Drug Delivery System. AZoNano. Retrieved on December 04, 2024 from https://www.azonano.com/news.aspx?newsID=17898.

  • MLA

    Arrowhead Pharmaceutical. "Leonardo Secures Grant to Commercialize Nanoparticle Drug Delivery System". AZoNano. 04 December 2024. <https://www.azonano.com/news.aspx?newsID=17898>.

  • Chicago

    Arrowhead Pharmaceutical. "Leonardo Secures Grant to Commercialize Nanoparticle Drug Delivery System". AZoNano. https://www.azonano.com/news.aspx?newsID=17898. (accessed December 04, 2024).

  • Harvard

    Arrowhead Pharmaceutical. 2019. Leonardo Secures Grant to Commercialize Nanoparticle Drug Delivery System. AZoNano, viewed 04 December 2024, https://www.azonano.com/news.aspx?newsID=17898.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.